EQL Pharma Zukünftiges Wachstum
Future Kriterienprüfungen 6/6
EQL Pharma is forecast to grow earnings and revenue by 45.7% and 26.1% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be 32.8% in 3 years.
Wichtige Informationen
45.7%
Wachstumsrate der Gewinne
45.7%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 34.2% |
| Wachstumsrate der Einnahmen | 26.1% |
| Zukünftige Eigenkapitalrendite | 32.8% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 18 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
Oct 29
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 640 | 129 | 75 | 115 | 1 |
| 3/31/2026 | 494 | 87 | 47 | 88 | 1 |
| 3/31/2025 | 429 | 69 | 26 | 67 | 2 |
| 6/30/2024 | 291 | 26 | -86 | -19 | N/A |
| 3/31/2024 | 264 | 23 | -78 | -11 | N/A |
| 12/31/2023 | 246 | 22 | -47 | 19 | N/A |
| 9/30/2023 | 256 | 28 | -11 | 12 | N/A |
| 6/30/2023 | 270 | 30 | -18 | 3 | N/A |
| 3/31/2023 | 260 | 31 | 7 | 28 | N/A |
| 12/31/2022 | 403 | 33 | 15 | 29 | N/A |
| 9/30/2022 | 440 | 39 | 34 | 51 | N/A |
| 6/30/2022 | 419 | 36 | 41 | 63 | N/A |
| 3/31/2022 | 410 | 32 | 20 | 42 | N/A |
| 12/31/2021 | 233 | 19 | -6 | 49 | N/A |
| 9/30/2021 | 145 | 4 | -24 | 40 | N/A |
| 6/30/2021 | 117 | 2 | -66 | -5 | N/A |
| 3/31/2021 | 179 | 10 | 4 | 60 | N/A |
| 12/31/2020 | 172 | 17 | -10 | 28 | N/A |
| 9/30/2020 | 163 | 16 | -5 | 20 | N/A |
| 6/30/2020 | 157 | 14 | 50 | 65 | N/A |
| 3/31/2020 | 72 | 3 | -11 | 7 | N/A |
| 12/31/2019 | 68 | 2 | -13 | 3 | N/A |
| 9/30/2019 | 58 | -2 | -2 | 14 | N/A |
| 6/30/2019 | 54 | -2 | -12 | 8 | N/A |
| 3/31/2019 | 50 | -2 | -10 | 6 | N/A |
| 12/31/2018 | 43 | -2 | 1 | 10 | N/A |
| 9/30/2018 | 41 | 0 | N/A | N/A | N/A |
| 6/30/2018 | 35 | 0 | -22 | -3 | N/A |
| 3/31/2018 | 32 | -1 | N/A | -2 | N/A |
| 12/31/2017 | 30 | 1 | N/A | -4 | N/A |
| 9/30/2017 | 30 | 0 | N/A | -11 | N/A |
| 6/30/2017 | 26 | 0 | N/A | -7 | N/A |
| 3/31/2017 | 24 | 0 | N/A | 1 | N/A |
| 12/31/2016 | 31 | 4 | N/A | 1 | N/A |
| 9/30/2016 | 29 | 5 | N/A | 10 | N/A |
| 6/30/2016 | 34 | 6 | N/A | 6 | N/A |
| 3/31/2016 | 35 | 7 | N/A | 2 | N/A |
| 12/31/2015 | 29 | 4 | N/A | 0 | N/A |
| 9/30/2015 | 26 | 1 | N/A | -9 | N/A |
| 6/30/2015 | 21 | -2 | N/A | -7 | N/A |
| 3/31/2015 | 19 | -5 | N/A | -11 | N/A |
| 12/31/2014 | 18 | -9 | N/A | -12 | N/A |
| 9/30/2014 | 19 | -11 | N/A | -9 | N/A |
| 6/30/2014 | 19 | -12 | N/A | -8 | N/A |
| 3/31/2014 | 20 | -11 | N/A | -6 | N/A |
| 12/31/2013 | 22 | -8 | N/A | -6 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: EQL's forecast earnings growth (45.7% per year) is above the savings rate (1.1%).
Ertrag vs. Markt: EQL's earnings (45.7% per year) are forecast to grow faster than the Swedish market (15.7% per year).
Hohe Wachstumserträge: EQL's earnings are expected to grow significantly over the next 3 years.
Einnahmen vs. Markt: EQL's revenue (26.1% per year) is forecast to grow faster than the Swedish market (0.01% per year).
Hohe Wachstumseinnahmen: EQL's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: EQL's Return on Equity is forecast to be high in 3 years time (32.8%)